tiprankstipranks
Trending News
More News >
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
US Market
Advertisement

Tarsus Pharmaceuticals (TARS) Stock Forecast & Price Target

Compare
249 Followers
See the Price Targets and Ratings of:

TARS Analyst Ratings

Strong Buy
7Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Tarsus
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TARS Stock 12 Month Forecast

Average Price Target

$74.17
▲(6.34% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Tarsus Pharmaceuticals in the last 3 months. The average price target is $74.17 with a high forecast of $85.00 and a low forecast of $44.00. The average price target represents a 6.34% change from the last price of $69.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"$31","86":"$86","44.75":"$44.8","58.5":"$58.5","72.25":"$72.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$85.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$74.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$44.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,44.75,58.5,72.25,86],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.34,59.46769230769231,61.59538461538462,63.723076923076924,65.85076923076923,67.97846153846154,70.10615384615384,72.23384615384616,74.36153846153846,76.48923076923077,78.61692307692307,80.74461538461539,82.87230769230769,{"y":85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.34,58.63461538461539,59.92923076923077,61.223846153846154,62.518461538461544,63.81307692307693,65.1076923076923,66.40230769230769,67.69692307692308,68.99153846153847,70.28615384615385,71.58076923076923,72.87538461538462,{"y":74.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.34,56.31384615384616,55.28769230769231,54.261538461538464,53.23538461538462,52.20923076923077,51.183076923076925,50.15692307692308,49.13076923076923,48.104615384615386,47.07846153846154,46.05230769230769,45.026153846153846,{"y":44,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.29,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.76,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.48,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$85.00Average Price Target$74.17Lowest Price Target$44.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on TARS
Bank of America Securities
Bank of America Securities
$80$85
Buy
21.86%
Upside
Reiterated
10/09/25
Bank of America Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)
William Blair
Buy
Reiterated
09/26/25
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)We believe this rapid adoption supports the effectiveness of the company’s efforts to drive broader prescribing, but also indicates the positive experience that doctors have had with Xdemvy, as we believe they would be unlikely to broaden their prescribing if they had been unsatisfied with the results of the product to date. While this broad use is an encouraging sign and provides some validation of the company’s estimated target market of 9 million patients, management noted that most ECPs are still in the very early stages of expanding their prescribing across patient segments, having prescribed Xdemvy to only a handful of patients in some segments.
H.C. Wainwright Analyst forecast on TARS
H.C. Wainwright
H.C. Wainwright
$72
Buy
3.23%
Upside
Reiterated
09/17/25
H.C. Wainwright Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)
Oppenheimer
$75
Buy
7.53%
Upside
Reiterated
08/13/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe reiterate Outperform.
LifeSci Capital Analyst forecast on TARS
LifeSci Capital
LifeSci Capital
$85
Buy
21.86%
Upside
Reiterated
08/07/25
Tarsus Pharmaceuticals: Strong Sales Growth and Strategic Initiatives Drive Buy Rating
Guggenheim Analyst forecast on TARS
Guggenheim
Guggenheim
$84
Buy
20.43%
Upside
Reiterated
08/06/25
Guggenheim Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)
Goldman Sachs Analyst forecast on TARS
Goldman Sachs
Goldman Sachs
$44
Hold
-36.92%
Downside
Reiterated
07/15/25
Tarsus Pharmaceuticals (TARS) Receives a Hold from Goldman Sachs
Jefferies
$54$58
Buy
-16.85%
Downside
Reiterated
03/06/25
Tarsus Pharmaceuticals (TARS) PT Raised to $58 at JefferiesJefferies analyst Anthony Petrone raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $58.00 (from $54.00) while maintaining a Buy rating.
Barclays
$62$60
Buy
-13.98%
Downside
Reiterated
03/06/25
Barclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on TARS
Bank of America Securities
Bank of America Securities
$80$85
Buy
21.86%
Upside
Reiterated
10/09/25
Bank of America Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)
William Blair
Buy
Reiterated
09/26/25
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)We believe this rapid adoption supports the effectiveness of the company’s efforts to drive broader prescribing, but also indicates the positive experience that doctors have had with Xdemvy, as we believe they would be unlikely to broaden their prescribing if they had been unsatisfied with the results of the product to date. While this broad use is an encouraging sign and provides some validation of the company’s estimated target market of 9 million patients, management noted that most ECPs are still in the very early stages of expanding their prescribing across patient segments, having prescribed Xdemvy to only a handful of patients in some segments.
H.C. Wainwright Analyst forecast on TARS
H.C. Wainwright
H.C. Wainwright
$72
Buy
3.23%
Upside
Reiterated
09/17/25
H.C. Wainwright Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)
Oppenheimer
$75
Buy
7.53%
Upside
Reiterated
08/13/25
Wall Street Analysts Are Bullish on Top Healthcare PicksWe reiterate Outperform.
LifeSci Capital Analyst forecast on TARS
LifeSci Capital
LifeSci Capital
$85
Buy
21.86%
Upside
Reiterated
08/07/25
Tarsus Pharmaceuticals: Strong Sales Growth and Strategic Initiatives Drive Buy Rating
Guggenheim Analyst forecast on TARS
Guggenheim
Guggenheim
$84
Buy
20.43%
Upside
Reiterated
08/06/25
Guggenheim Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)
Goldman Sachs Analyst forecast on TARS
Goldman Sachs
Goldman Sachs
$44
Hold
-36.92%
Downside
Reiterated
07/15/25
Tarsus Pharmaceuticals (TARS) Receives a Hold from Goldman Sachs
Jefferies
$54$58
Buy
-16.85%
Downside
Reiterated
03/06/25
Tarsus Pharmaceuticals (TARS) PT Raised to $58 at JefferiesJefferies analyst Anthony Petrone raised the price target on Tarsus Pharmaceuticals (NASDAQ: TARS) to $58.00 (from $54.00) while maintaining a Buy rating.
Barclays
$62$60
Buy
-13.98%
Downside
Reiterated
03/06/25
Barclays Sticks to Their Buy Rating for Tarsus Pharmaceuticals (TARS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tarsus Pharmaceuticals

1 Month
xxx
Success Rate
11/15 ratings generated profit
73%
Average Return
+8.63%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +8.63% per trade.
3 Months
xxx
Success Rate
12/15 ratings generated profit
80%
Average Return
+13.94%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +13.94% per trade.
1 Year
Eddie HickmanGuggenheim
Success Rate
8/8 ratings generated profit
100%
Average Return
+72.13%
reiterated a buy rating 2 months ago
Copying Eddie Hickman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +72.13% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
100%
Average Return
+119.77%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +119.77% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TARS Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
5
7
7
6
4
Buy
2
2
3
4
5
Hold
3
3
6
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
12
16
15
13
In the current month, TARS has received 9 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TARS average Analyst price target in the past 3 months is 74.17.
Each month's total comprises the sum of three months' worth of ratings.

TARS Financial Forecast

TARS Earnings Forecast

Next quarter’s earnings estimate for TARS is -$0.36 with a range of -$0.51 to -$0.17. The previous quarter’s EPS was -$0.48. TARS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TARS has Preformed in-line its overall industry.
Next quarter’s earnings estimate for TARS is -$0.36 with a range of -$0.51 to -$0.17. The previous quarter’s EPS was -$0.48. TARS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TARS has Preformed in-line its overall industry.

TARS Sales Forecast

Next quarter’s sales forecast for TARS is $113.05M with a range of $109.93M to $118.92M. The previous quarter’s sales results were $102.66M. TARS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TARS has Preformed in-line its overall industry.
Next quarter’s sales forecast for TARS is $113.05M with a range of $109.93M to $118.92M. The previous quarter’s sales results were $102.66M. TARS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TARS has Preformed in-line its overall industry.

TARS Stock Forecast FAQ

What is TARS’s average 12-month price target, according to analysts?
Based on analyst ratings, Tarsus Pharmaceuticals’s 12-month average price target is 74.17.
    What is TARS’s upside potential, based on the analysts’ average price target?
    Tarsus Pharmaceuticals has 6.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TARS a Buy, Sell or Hold?
          Tarsus Pharmaceuticals has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Tarsus Pharmaceuticals’s price target?
            The average price target for Tarsus Pharmaceuticals is 74.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $85.00 ,the lowest forecast is $44.00. The average price target represents 6.34% Increase from the current price of $69.75.
              What do analysts say about Tarsus Pharmaceuticals?
              Tarsus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of TARS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis